Utama › Limfoma Sel B Besar Difus › Kentucky
Kajian klinikal Limfoma Sel B Besar Difus di Kentucky
11 kajian untuk Limfoma Sel B Besar Difus sedang mencari peserta di lokasi di Kentucky.
Bandar di Kentucky
Teks kajian rasmi (Bahasa Inggeris)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- University of Kentucky Medical Center, Lexington
- University of Louisville Health Brown Cancer Center, Louisville
- Norton Cancer Institute, Louisville
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06500273A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- University of Kentucky ( Site 0106), Lexington
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163), Louisville
- Owensboro Medical Health System ( Site 0195), Owensboro
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- University of Kentucky, Lexington
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06091865A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Saint Elizabeth Medical Center Edgewood ( Site 0141), Edgewood
- Baptist Health Hardin ( Site 0154), Elizabethtown
- Baptist Health Lexington ( Site 0127), Lexington
- dan 1 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06890884Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- University of Kentucky - Markey Cancer Center, Lexington
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT06806033A Study of ARC-02 in B-cell NHL
- Norton Cancer Institute, Louisville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Louisville Brown Cancer Center, Louisville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Louisville Health, Louisville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT07188558The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Norton Cancer Institute, Louisville
Mengambil pesertaFasa 1/2
Umur 12 hingga 95 · Semua jantina · Dikemas kini 15 Apr 2026 · NCT04329728Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Feb 2026 · NCT05633615Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.